Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)

Phase Distribution

Ph phase_3
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_3

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

NCT05181540
completedphase_1

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

NCT03925935

Clinical Trials (2)

Showing 2 of 2 trials
NCT05181540Phase 3

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
NCT03925935Phase 1

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Completed

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2